Bišpecifické protilátky v liečbe mnohopočetného myelómu // SOLEN

Onkológia 6/2025

Bispecific antibody in the treatment of multiple myeloma

The prognosis of patients with relapsed or refractory multiple myeloma is poor. Treatment with bispecific antibodies (BsAb) has significantly improved the treatment responses and survival of patients with RR MM, but also brought new challenges in their overall management. Curently, three drugs are approved in Europe for the treatment of RR MM: elranatamab, talquetamab, teclistamab.

Keywords: multiple myeloma, elranatamab, talquetamab, teclistamab, toxicity